Used for the relief of hay fever and allergies, Galpharm cetirizine hydrochloride tablets help to prevent symptoms for up to 24 hours. Patients on hemodialysis (creatinine clearance less than 7 ml/min) given a single oral 10 mg dose of cetirizine had a 3-fold increase in half-life and a 70 % decrease in clearance compared to normals. hydrochloride, Chlorphenamine, Clarityn, Galpharm, Haylief, Loratadine, Murine, Nasaleze, Numark, Opticrom, Optrex, Otrivine, Pirinase, Piriteze, pollenase and Sterimar. Patients intending to drive, engaging in potentially hazardous activities or operating machinery should not exceed the recommended dose and should take their response to the medicinal product into account.

Hayfever and Allergy Relief 10mg Tablets (Cetirizine Hayfever and Allergy Relief 10mg Tablets (Cetirizine

Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take cetirizine film-coated tablet. Clinical studies have shown that cetirizine at the recommended dosage has minor undesirable effects on the CNS, including somnolence, fatigue, dizziness and headache. In some cases, paradoxical CNS stimulation has been reported. In a 35-day study in children aged 5 to 12, no tolerance to the antihistaminic effect (suppression of wheal and flare) of cetirizine was found. When a treatment with cetirizine is stopped after repeated administration, the skin recovers its normal reactivity to histamine within 3 days. In a six-week, placebo-controlled study of 186 patients with allergic rhinitis and concomitant mild to moderate asthma, cetirizine 10 mg once daily improved rhinitis symptoms and did not alter pulmonary function. This study supports the safety of administering cetirizine to allergic patients with mild to moderate asthma. At therapeutic doses, no clinically significant interactions have been demonstrated with alcohol (for a blood alcohol level of 0.5g/L). Nevertheless, precaution is recommended if alcohol is taken concomitantly.Renally impaired patients: The pharmacokinetics of the drug were similar in patients with mild impairment (creatinine clearance higher than 40 ml/min) and healthy volunteers. Patients with moderate renal impairment had a 3-fold increase in half-life and 70 % decrease in clearance compared to healthy volunteers. These tablets should always be kept out of sight and reach of children. Will taking Galpharm Cetirizine and Hydrochloride tablets make you drowsy? Studies in healthy volunteers show that cetirizine, at doses of 5 and 10 mg strongly inhibits the wheal and flare reactions induced by very high concentrations of histamine into the skin, but the correlation with efficacy is not established.

Galpharm Hayfever and Allergy Relief - Boots

Galpharm antihistamine tablets do not cause drowsiness in most people. However, as with other antihistamines, rare cases of drowsiness have been reported. If affected do not drive or operate machinery. As with all antihistamines, you should avoid excessive alcohol consumption when taking this medicine. Can you take Galpharm Cetirizine and Hydrochloride tablets when pregnant or breastfeeding? Galpharm antihistamine tablets provide relief from the symptoms of hay fever and other airborne allergies. Galpharm Hay fever and Allergy Relief tablets can also be taken for skin allergies such as rash, itching, and urticaria (hives). The active ingredient in Galpharm antihistamine is Cetirizine, which is known as a non-drowsy antihistamine. It's much less likely to make you feel sleepy than some other antihistamines.Very common (>1/10); common (>1/100 to <1/10); uncommon (>1/1,000 to 1/100); rare (> 1/10,000 to 1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data) Elderly: Following a single 10 mg oral dose, half-life increased by about 50 % and clearance decreased by 40 % in 16 elderly subjects compared to the normal subjects. The decrease in cetirizine clearance in these elderly volunteers appeared to be related to their decreased renal function. Although statistically more common than under placebo, somnolence was mild to moderate in the majority of cases. Objective tests as demonstrated by other studies have demonstrated that usual daily activities are unaffected at the recommended daily dose in healthy young volunteers. In addition to its anti-H1 effect, cetirizine was shown to display anti-allergic activities: at a dose of 10 mg once or twice daily, it inhibits the late phase recruitment of eosinophils, in the skin and conjunctiva of atopic subjects submitted to allergen challenge.

Galpharm Hay Fever and Allergy Relief 14 Tablets | medino

The apparent volume of distribution is 0.50 l/kg. Plasma protein binding of cetirizine is 93 ± 0.3%. Allergy skin tests are inhibited by antihistamines and a wash-out period (of 3 days) is required before performing them. Objective measurements of driving ability, sleep latency and assembly line performance have not demonstrated any clinically relevant effects at the recommended dose of 10mg. History of hypersensitivity to any of the constituents of the formulation, to hydroxyzine or to any piperazine derivatives. Rare: hepatic function abnormal (increased transaminases, alkaline phosphatase, y-GT and bilirubin)Double blind controlled clinical trials comparing cetirizine to placebo or other antihistamines at the recommended dosage (10 mg daily for cetirizine), of which quantified safety data are available, included more than 3200 subjects exposed to cetirizine. Patients with hepatic impairment: no dose adjustment is needed in patients with solely hepatic impairment. Do not exceed the stated dose when taking Galpharm Hay fever and Allergy Relief Cetirizine Hydrochloride. If symptoms persist whilst taking this medication, consult your doctor.

Galpharm Cetirizine Hayfever and Allergy Relief Tablets

Cetirizine was poorly cleared by haemodialysis. Dosing adjustment is necessary in patients with moderate or severe renal impairment (see section 4.2). The distribution of pharmacokinetic parameters such as peak plasma concentration (Cmax) and area under curve (AUC), is unimodal in human volunteers. The extent of absorption of cetirizine is not reduced with food, although the rate of absorption is decreased. The extent of bioavailability is similar when cetirizine is given as solutions, capsules or tablets. Cetirizine is excreted in human milk at concentrations representing 25% to 90% of those measured in plasma, depending on sampling time after administration. Therefore, caution should be exercised when prescribing cetirizine to lactating women. Instances of abnormal hepatic function with elevated hepatic enzymes accompanied by elevated bilirubin have been reported. Mostly this resolves upon discontinuation of the treatment with cetirizine dihydrochloride. For cetirizine very rare clinical data on exposed pregnancies are available. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development. Caution should be exercised when prescribing to pregnant women.Cetirizine does not undergo extensive first pass metabolism. About two third of the dose are excreted unchanged in urine. The terminal half-life is approximately 10 hours. Hepatically impaired patients: Patients with chronic liver diseases (hepatocellular, cholestatic, and biliary cirrhosis) given 10 or 20 mg of cetirizine as a single dose had a 50 % increase in half-life along with a 40 % decrease in clearance compared to healthy subjects. Caution should be taken in patients with predisposition factors of urinary retention (e.g. spinal cord lesion, prostatic hyperplasia) as cetirizine may increase the risk of urinary retention. Elderly subjects: data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function is normal. Patients with moderate to severe renal impairment: there are no data to document the efficacy/safety ratio in patients with renal impairment. Since cetirizine is mainly excreted via renal route (see section 5.2), in cases no alternative treatment can be used, the dosing intervals must be individualized according to renal function. Refer to the following table and adjust the dose as indicated. To use this dosing table, an estimate of the patient’s cre­atinine clearance (CLcr) in ml/min is needed. The CLcr (ml/min) may be estimated from serum creatinine (mg/dl) determination using the following formula: